PubMed Health⌕ Search

PubMed · 3619709

Complex partial seizures of infancy.

Abstract

Ictal manifestations of complex partial seizures in infancy have not been described previously. Using long-term video/electroencephalographic and telemetric monitoring techniques, 187 seizures were recorded in 14 infants under 2 years of age. With one exception, the infants were profoundly delayed with intractable seizures. Nine had marked bilateral abnormalities on computed tomographic scan. The seizure manifestations noted most frequently consisted of behavioral arrest with forced lateralized deviation of the head and eyes and tonic upper-extremity extensor stiffening. Complex facial automatisms such as chewing, sucking, mouthing, and blinking were relatively common. Ictal paroxysmal onset was always lateralized on electroencephalograms, whereas the interictal recordings revealed multifocal epileptic discharges, generalized slowing, and voltage attenuation. The ictal behavioral manifestations and electric seizure patterns were quite distinctive yet were often undiagnosed on routine evaluations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M S Duchowny. 1987. Complex partial seizures of infancy.. https://doi.org/10.1001/archneur.1987.00520210013011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗